265114-23-6

Cimicoxib is a non-steroidal anti-inflammatory drug (NSAID) that inhibits COX-2 selectively over COX-1 (IC₅₀s = 0.005 and 3.3 μM, respectively). It inhibits paw swelling by 93% in a rat model of adjuvant-induced arthritis when administered at a dose of 1 mg/kg. Cimicoxib (3 mg/kg, p.o.) inhibits carrageenan-induced decreases in paw withdrawal latency in the hot plate test in a rat model of hyperalgesia. Formulations containing cimicoxib have been used in the treatment of pain and inflammation associated with osteoarthritis or surgery in dogs.

Cimicoxib is a long-acting COX-2 Inhibitor and is developed as a non-steroidal anti-inflammatory veterinary drug used to treat dogs with inflammation and pain associated with osteoarthritis.

4-[4-chloro-5-(3-fluoro-4-methoxy-phenyl)imidazol-1-yl]benzenesulfonam ide is an imidazole substituted at positions 1, 4 and 5 by 4-aminosulfonylphenyl, chloro and 3-fluoro-4-methyoxyphenyl groups respectively. A selective cyclooxygenase 2 inhibitor, it is used in veterinary medicine for the control of pain and inflammation associat d with osteoarthritis in dogs.

COX-2

[1] T.W. KIM . Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs[J]. Veterinary journal, 2014, 200 1: Pages 77-81. DOI: 10.1016/j.tvjl.2013.12.020
[2] CARMEN ALMANSA. Synthesis and Structure?Activity Relationship of a New Series of COX-2 Selective Inhibitors: 1,5-Diarylimidazoles[J]. Journal of Medicinal Chemistry, 2003, 46 16: 3463-3475. DOI: 10.1021/jm030765s